Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wensheng Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4357-1893; OpenAlex author ID A5100678274. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 5 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: none · 2024: 3 papers

Papers 23

  1. Evaluating the efficacy of laparoscopic radical antegrade modular pancreatosplenectomy in selected early-stage left-sided pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-024-10868-x↗
  2. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… Co-author DOI 10.1186/s12957-023-03277-2↗
  3. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  4. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  5. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  6. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  7. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.redox.2020.101807↗
  8. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  9. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  10. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  11. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Co-author DOI 10.1186/s12935-021-02210-5↗
  12. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  13. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  14. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  15. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  16. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  17. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  18. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  19. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗
  20. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  21. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  22. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Co-author DOI 10.7150/thno.26546↗
  23. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 22 shared papers, 2017–2024 · strength 2.45
  2. Shunrong Ji · 21 shared papers, 2017–2024 · strength 2.27
  3. Wenyan Xu · 19 shared papers, 2017–2024 · strength 2.03
  4. Xiaowu Xu · 17 shared papers, 2019–2024 · strength 1.95
  5. Yi Qin · 18 shared papers, 2017–2021 · strength 1.71
  6. Qiangsheng Hu · 18 shared papers, 2017–2021 · strength 1.71
  7. Qifeng Zhuo · 12 shared papers, 2020–2024 · strength 1.59
  8. Zheng Zhang · 13 shared papers, 2018–2021 · strength 1.27
  9. Mengqi Liu · 10 shared papers, 2019–2024 · strength 1.11
  10. Ye Zeng · 8 shared papers, 2020–2022 · strength 0.91
  11. Qiqing Sun · 10 shared papers, 2018–2020 · strength 0.89
  12. Quanxing Ni · 6 shared papers, 2017–2019 · strength 0.45
  13. Jin Xu · 6 shared papers, 2017–2019 · strength 0.45
  14. Ye Zeng · 4 shared papers, 2019–2021 · strength 0.43
  15. Chenjie Zhou · 2 shared papers, 2024 · strength 0.38
  16. Heli Gao · 2 shared papers, 2022–2024 · strength 0.33
  17. Xiaowu Xu · 2 shared papers, 2022–2024 · strength 0.33
  18. Mengqi Liu · 2 shared papers, 2021–2024 · strength 0.32
  19. Haidi Chen · 2 shared papers, 2021–2024 · strength 0.30
  20. Bo Zhang · 3 shared papers, 2018–2019 · strength 0.24
  21. Changfeng Song · 2 shared papers, 2021 · strength 0.24
  22. Wenyan Xu · 2 shared papers, 2019–2021 · strength 0.21
  23. Zheng Li · 1 shared paper, 2024 · strength 0.20
  24. Chen Chen · 1 shared paper, 2024 · strength 0.20
  25. Zheng Li · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.